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Abstract
The ability to engineer particles has the potential to shift the paradigm in the creation of new
medicines and diagnostics. Complete control over particle characteristics, such as size, shape,
mechanical property, and surface chemistry, can enable rapid translation and facilitate the US
Food and Drug Administration (FDA) approval of particle technologies for the treatment of
cancer, infectious diseases, diabetes, and a host of other major illnesses. The incorporation of
natural and artificial external stimuli to trigger the release of drugs enables exquisite control over
the release profiles of drugs in a given environment. In this article, we examine several readily
scalable top-down methods for the fabrication of shape-specific particles that utilize stimuli-
responsive biomaterials for controlled drug delivery. Special attention is given to Particle
Replication In Nonwetting Templates (PRINT®) technology and the application of novel
triggered-release synthetic and natural polymers.
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1. Introduction
The ability to engineer particles allows for precise control over the delivery of drugs and
diagnostic agents. Over the past two decades, significant progress has been made in the
development of particle systems that are capable of overcoming many biological barriers (ie.
PEGylated particles bypassing the reticuloendothelial system and intra-nuclear delivery of
drugs using nuclear localization signal peptide sequences) [1–3]. An important aspect of
particle-based medicines is the ability to deliver cargo to a site of interest. Stimuli-
responsive biomaterials enable effective site-specific delivery of drugs by exploiting
physiologic conditions in vivo. In this review, we examine natural stimuli-responsive
biomaterials for controlled drug delivery and several scalable top-down methods for
fabricating particles of the stimuli-responsive biomaterials.
1.1 Engineering Particle Systems: Top-Down versus Bottom-Up Fabrication Methods
The two major classes of particle fabrication are top-down and bottom-up methods. Bottom-
up particle fabrication methods build the particle from the atomic or molecular level with the
desired particle physical parameters, whereas top-down particle fabrication methods process
a material beginning at the macroscopic level to the desired size and shape scale. Medicines
made by bottom-up fabrication methods have received much attention for being the primary
drug delivery systems at the forefront of nanotechnology [4–7]. Bottom-up methods rely
upon the self-assembly of molecules for creation of particles such as micelles, vesicles,
liposomes, and polymersomes where drugs and diagnostic agents are encapsulated in the
interior of the particle [8]. The self-assembly process is readily scalable but lacks the fine
control over size, shape, and degradation.
Top down fabrication techniques allow for the simultaneous control over chemical
composition, particle size, shape, cargo, mechanical property, and surface chemistries
(antibodies, PEG chains, metal chelators) that can precisely realize intracellular delivery for
bioactivity. Lithography has expanded the top-down particle fabrication platform through
the development of patterned surfaces [9]. Photolithography, electron beam lithography, and
ion beam lithography allows for highly scalable patterned surfaces with smaller and smaller
feature sizes [10]. The generated patterned surfaces enable the techniques of molding,
embossing, and transfer printing [11]. These techniques are at the forefront of devising new
strategies to systematically engineer particles using stimuli-responsive biomaterials.
Currently, the emerging top-down strategies capable of controlling size and shape are
microfluidics, photolithographic methods, and imprint lithographic methods.
1.2. Important Factors in Particle Design
Long circulation times, reduction in secondary effects of drugs, accumulation in organs of
interest, biocompatibility, and controlled degradation are all factors of drug vehicles that
play important roles in the therapeutic efficacy. In this regard, particle design is a critical
determinant of the therapeutic efficacy of particle-based medicines. Both chemical and
physical properties of particles have been recognized as critical in the success of drug
delivery in vivo [12]. Surface chemistry has shown to reduce protein adsorption and
phagocytosis [13–17], or direct the particles to the target tissues [18, 19]. In the physical
aspect, the size plays a role in particle biodistribution. The particles less than 5 nm are
cleared rapidly from the circulation by extravasation or renal clearance [20, 21]. Spherical
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particles with the size range from 10 nm to 15 µm have been studied widely in terms of
biodistribution [22–24]. There have been several experimental examples of the impact of
size and shape on particle internalization and biodistribution. [25] Long cylindrical filaments
achieved via self-assembly of block copolymer into worm-like micelles, displayed
negligible phagocytosis compared with spheres of a similar volume [26]. In a separate study,
the investigation of spherical and elliptical disk-shape polystyrene microparticles during
phagocytosis by alveolar macrophages indicated that macrophages internalized particles
along the major axis while particles were not internalized along the minor axis after 12 hours
[27]. Red blood cell mimics (~6 µm) have shown that the micrometer-sized deformable
particles can bypass several organs. These red blood cell mimics were used to mimic the
mechanical properties of red blood cell, showing an 8-fold decrease in Young’s modulus
correlated to a greater than 3-fold increase in the elimination half-life [28]. Additionally,
particle matrix also plays an important role in drug delivery. Stimuli-responsive biomaterials
and natural polymers enable exquisite control over the release of drug at the site of action.
2. Stimuli-Responsive Biomaterials used in Engineered Particle Systems
Considerable effort has been devoted to controlling the release of cargo and the degradation
of the particle. Particles made up of stimuli-responsive materials have been developed to
release their encapsulated cargo in extracellular and intracellular compartments. This control
of drug delivery enables more specificity in drug accumulation and reduced non-specific
toxicity. Triggered release of the drug is made possible through artificial stimuli [29], such
as light-irradiation, magnetic, ultrasonic, thermal, and electric, as well as natural stimuli,
such as pH changes [30], redox gradients [31], and enzymatic stimuli [32]. Natural stimuli
within pathways of cellular uptake or tissue environments are emerging as major triggers for
designing engineered particles, since they happen spontaneously in vivo, avoiding the use of
any extra assistance. In general, the characteristics of a clinically relevant particle matrix
should be i) non-toxic, ii) capable of maintaining good mechanical integrity until
degradation, and iii) controlled degradation profile. In addition, the degradation byproducts
should be also non-toxic and cleared by the body. In regard to these aspects, biodegradable
polymers and hydrogels with cleavable linkers that respond to natural stimuli have gained
tremendous research interest in the area of biodegradable particle fabrication. Practical
examples of biomaterials responding to natural pH gradients, redox gradients, and enzymatic
catalysis are discussed in more detail below.
2.1 pH Gradients
Certain tumors and inflamed tissue have a slightly lower pH values (between pH 5.4 and
7.4) than homeostatic conditions (pH 7.4) [33, 34]. Furthermore, there exists a lower
intracellular pH in endosomes and lysosomes. As such, particles internalized through
endocytosis will experience a pH gradient from neutral (pH~7.4) in extracellular
environment, to acidic (pH~6.2) in early endosome and more acidic (pH~5.0) in lysosome.
[35]. Acid-cleavable biomaterials have been used to generate engineered particles to be
degraded by the pH change from extracellular compartment to the intracellular endosome.
Specifically, the linkers having acidic labile groups such as hydrazones, trityls, aconityls,
vinyl ethers, polyketals, acetals, poly(orthoesters), thiopropionates, and silyl ethers [36–44].
2.2 Redox Gradients
In eukaryotic cells, disulfide bonds between cysteines within proteins are formed in the
endoplasmic reticulum (ER) to fortify the protein tertiary structure [31]. The lumen of the
ER has an oxidizing environment, as the glutathione (GSH):glutathione disulfide (GSSG)
ratio is estimated to be 1:3. The redox state of GSH in cytosol is biased to a greatly reduced
state as a result of a ratio of GSH to GSSG, which is greater than 100 in most cells. This
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ratio is maintained by the catalytic conversion of GSSG to GSH by glutathione reductase
and NADPH [45]. In contrast to 1–10 mM glutathione in the cytosol, glutathione (GSH)
concentration in the extracellular environment is much lower, typically ~10 µM in plasma
[46]. Thus, there is a redox gradient existing between extracellular environment and the
reducing intracellular space. Reductively labile linkers containing disulfide bonds can be
used for degradation upon cellular internalization, since the reduction of disulfide bond is
initiated by the redox gradient in the pathways of endosome and lysosome [47].
2.3 Enzymatic Stimuli
Almost all cellular processes require the assistance of enzymes. Substrate specificity enables
enzymes to be highly selective. Materials that can be digested by specific enzymes are
regarded as promising candidates for fabricating drug carriers. Three major examples of
enzyme-triggered release of drugs are the controlled release of insulin by glucose oxidase
through an acid-labile linker [48–50], dextran particles degraded by dextranase [51], and
protein based particles digested by protease [52, 53]. The pathogenesis of diabetes (type 1
and type 2) involves the inability of the pancreas to control blood glucose concentration by
the reduced secretion of insulin [54]. Glucose oxidase triggers the conversion of glucose to
gluconic acid, thus increasing the local proton concentration, which allows for a platform of
controlled release of insulin from the pH-sensitive systems [48–50]. As an example of
microbial enzymes, dextranase is always present in the colon, triggering the degradation of
polysaccharide dextran. As such, the dextran-based particles break apart, inducing a release
of encapsulated drugs into human colons [51]. Protease, a proteolytic enzyme, begins
protein catabolism by hydrolysis of the peptide bonds in the polypeptide chain. Proteases are
currently classified into six broad groups, including serine proteases, threonine proteases,
cysteine proteases, aspartate proteases, metalloproteases, and glutamic acid proteases [52,
53]. These different proteases differ in substrate specificity. Tailored by the proteolytic
hydrolysis in the presence of specific protease, proteins can be degraded into nontoxic short
peptides or amino acids. At this point, proteins are being widely evaluated as an essential
family of biopharmaceutical substances for creating new drug vehicles.
3. Methods for Engineering Stimuli-Responsive Particles
There are many different top-down methods for fabricating particles with a variety of
physical and chemical characteristics. We have highlighted a number of top-down methods
that can be used to fabricate particles made up of stimuli-responsive materials, as
summarized in Table 1.
3.1. Microfluidic Particle fabrication
Particle fabrication using microfluidic channels is an emerging strategy for the creation of
particles with control over size and shape. The microfluidic channel is routinely replicated
using polydimethylsiloxane (PDMS) or polyurethane (PU) from a patterned surface
prepared by SU-8 photoresist on silicon wafers. The minimum feature size is determined by
the lithographic method. Two microfluidic apparatuses, T-junction microchannel (Fig. 1A-a)
[55, 56] and the planar flow-focusing device (FFD) (Fig. 1A-b) [57] are broadly
implemented in particle fabrication [58–61]. In principle, shear forces exerted by a flowing
continuous phase creates a micrometer-sized monodisperse emulsion droplet. The emulsion
drop size in the continuous phase is determined by a dimensionless parameter Qd/Qc and the
capillary number Cawhere Qd and Qc are the flow rates of dispersed phase and continuous
phase, respectively, and Ca is the ratio of shear force exerted by the continuous phase to the
surface force at the interface of the emulsion drops [56]. In addition, drops of dispersed
phased in T-junctions can be separated by a shear force created by the flow of continuous
phase. The size (10 µm ~ 200 µm) and shape (sphere or elongated) can be well tuned by the
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channel width and flow rates. In the FFD device, a coaxially flowing continuous phase fluid
flanks the dispersed phase on both sides, breaking off the droplet immediately after a narrow
orifice [57]. Not only spheres and ellipsoids but also cylinders and discs can be generated by
FFD. The shape of the particle is dependent on the narrow orifice where the dispersed phase
is broken up [62]. There are several approaches to solidify the emulsion droplets and form
robust particles, such as cooling the droplets below their melting point, evaporating the
solvents from the solid polymers, photo-curing or thermal polymerization of the emulsion
droplets containing reactive reagents.
In addition, a new type of flow lithography approach, continuous-flow lithography (CFL)
(Fig. 1B), was reported to produce particles with more complex shapes in microfluidic
devices [63]. A photomask with a unique shape is covered on a microfluidic channel,
allowing a flowing stream of photocurable monomers to be selectively exposed to the UV
light. The monomers in the UV-exposure region are crosslinked into solid particles. The
surface polymerization of the particles is inhibited by flowing oxygen along the inner wall
of the microfluidic channel, inducing an uncrosslinked layer which enables the particles to
flow out of the channels without sticking to the channel wall. Photomasks can be chosen
expanding the particle shapes from the spheres generated by droplet-based method to several
others, e. g. triangles, circles, squares, rings, etc. However, particle size is limited by the
CFL method because of blurring and smearing of the particles. This is overcome by stop-
flow lithography (SFL), a process during which the flow of monomer is temporarily stopped
during each photo-curing step [64]. Because of the nature of this fabrication method, there
are some limitations to this technique: i) formulations of the particles, ii) size of the particle,
and iii) solvents of the dispersed phase without swelling the microfluidic channel. A variety
of photocurable crosslinkers consisting of pH-cleavable, reductively labile, enzyme-
responsive, or antigen-sensitive moieties have been designed and studied in many traditional
hydrogel systems [31, 32, 34, 65, 66]. In the area of drug delivery, there is significant
potential for the microfluidic fabrication of particles made with stimuli-responsive materials.
Biodegradable polymers such as poly(lactic acid-glycolic acid) (PLGA) have been broadly
used as matrices for drug delivery [67, 68]. PLGA has been successful as a biodegradable
polymer because it undergoes hydrolysis in the body to produce the original monomers,
lactic acid and glycolic acid. These two monomers are by-products of various metabolic
pathways in the body. There is very minimal systemic toxicity associated with PLGA for
drug delivery or biomaterial applications. PLGA degrades by hydrolysis of its ester linkages
in the presence of water, which can shift the local pH when PLGA is given in large
quantities. [69] It has been shown that the time required for degradation of PLGA is related
to the monomers' ratio used in production: the higher the content of glycolide units, the
longer the degradation time. An exception to this rule is the copolymer with a 50:50
monomer ratio that exhibits faster degradation [70].
Anderson et al. demonstrated the fabrication of monodisperse, drug-encapsulated PLGA
microparticles using the microfluidic flow-focusing device (FFD) [71]. The dispersed phase
was composed of PLGA, drug (bupivacaine), and dichloromethane while an aqueous
solution containing 1% poly(vinyl alcohol) (PVA) was utilized as a continuous phase. The
emulsion droplets were collected in a buffer solution (pH 8.5) that minimized the particle
aggregation and leaching of bupivacaine. Solid PLGA particles encapsulating drugs resulted
after evaporating organic solvent, and the particle size was well-tuned by adjusting the
flowing rates of the two phases. Drug release studies indicated that smaller particles released
cargos faster than the bigger particles, which was due to the larger surface area-to-volume
ratio of the smaller particles. In comparison to the particles produced by conventional
emulsion methods with the similar average size, the microfluidic particles released drugs
relatively slower. In addition, the initial burst release of drug from monodisperse
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microfluidic particles was significantly reduced than that observed from corresponding
polydisperse conventional solvent emulsification particles, as shown in Fig. 2. The
difference in drug release between the two kinds of particles was attributed to a difference in
drug entrapment in the particles. Less drug was adsorbed or trapped close to the surface of
microfluidic particles, suggesting that microfluidic fabrication can homogenously mix all the
components in the dispersed phase leading to the particle fabrication with uniform drug
distribution.
Nanometer sized particles can be created by using a diblock polymer of poly(lactic acid-
glycolide)-b-poly(ethylene glycol) (PEG-PLGA) in a microfluidic device [72]. PEG-PLGA
dissolved in acetonitrile was directed through a microfludic channel, rapidly mixing with
another flowing water phase. The nanoprecipitation of hydrophobic PLGA segments was
induced by the solvent diffusion, resulting in formation of self-assembled particles in
microfluidic devices. Rapid solvent mixing by hydrodynamic flow focusing can overcome
the size limitation existing in conventional self-assembly processes. This is because the
solvent diffusion can be tuned faster than the polymer chain aggregation via increased
flowing rates, leading to smaller sized particles. The PEG-PLGA particle in this example
had an average size around 30 nm, which is much smaller than that (over 100 nm) produced
by well-known bulk methods. Although the co-precipitation with PLGA polymer increased
the size of the particle, hydrodynamic flow focusing prevented nanoparticle aggregation
resulting in smaller and more homogeneous nanoparticles. In contrast, the addition of PLGA
in the PEG-PLGA decreased the barrier nanoparticle/polymer aggregation and favored the
formation of larger polydisperse nanoparticles in bulk synthesis. Further studies indicated
that the incorporation of PLGA in the particle can enhance the drug loading and
encapsulation efficiency while decreasing the drug release rate. However, rather than
traditional emulsion methods, the synthesis of nanoparticles by self-assembly of block
copolymer precursors in microfluidic devices could enable better control over the
nanoparticle size, homogeneity, and drug loading and release.
Moreover, the self-assembly of biodegradable block copolymers in the microfluidic
channels can also generate polymersomes, having a similar bilayer structure to vesicles [73].
A triphase emulsion droplet, W/O/W, was formed in the dripping regime from a small
injection tube in a co-flow geometry with the middle oil stream containing the inner drops
being flow-focused by the outer continuous phase, breaking up into double emulsion drops.
Amphiphilic diblock copolymer poly(ethylene glycol)-b-poly(lactic acid) dispersed in the oil
phase consisting of toluene and chloroform moved to the W/O interface to stabilize the
emulsion droplet. After the evaporation of the organic solvent, monodisperse polymersomes
were obtained, which could be designed as carriers for the encapsulation of hydrophilic
cargos.
Lastly, microgels with a network structure are attracting considerable attention as smart
matrices in drug delivery. Microfluidic methods have become effective techniques for
fabricating monodisperse microgel particles, composed of agarose, alginate, or photocurable
organic prepolymers [74–78]. Photopolymerized microfluidic microgel particles can be
prepared using two different processes. One method is direct photopolymerization of
emulsion droplets containing photocurable prepolymers in either T-junction or FFD devices.
Another method is selective photopolymerization of prepolymer solution in CFL or SFL
devices, generating more complex structures than the former method. An introduction of
labile linkages within a prepolymer can be applied to trigger the release of drug and
degradation of the microgel for controlled drug delivery. One example was the
photopolymerization of emulsion droplets containing dextran-hydroxyethyl methacrylate
(dex-HEAMA) in FFD microfluidic device [79]. The resulting particles with an average size
of 9.9 µm exhibited much better uniformity than those prepared by conventional emulsion
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method. The hydrolysis of carbonate ester groups within the microgel network led to the
separated dextran chains and polymerized methacrylate groups, resulting in the gradual
particle degradation. In another example, a biodegradable polymer, poly(lactic acid), was
used as a labile linkage in a photocurable prepolymer, diacrylate PLA-b-PEG-b-PLA [80].
The shape-specific microgel particles were fabricated in SFL devices with a desired pulse of
UV exposure through a photomask. PLA degradation was found to induce cargo release and
a drop in the Young’s modulus of the microgel particles.
3.2. Photolithographic Methods
Photolithography has been exploited for the fabrication of discrete monodisperse particles
[65, 81–83]. The basic principle of photolithography for generating particles is similar to the
fabrication of patterned surfaces. In the particle fabrication process, as seen in Fig. 3a
substrate is coated with a sacrificial layer and subsequently with a layer of photocurable
prepolymer. The prepolymer layer is allowed to be selectively exposed to UV light through
a mask with shape- and size-specific features. As the prepolymer exposed to UV light is
photopolymerized, the uncured prepolymer and the sacrificial layer are both washed away,
resulting in the free particles. Some early monodisperse lithographical particles generated
from photoresist have been broadly exploited for the directed colloidal self-assembly [84].
However, photoresist-based particles are limited in their toxicity and poor degradation for
drug delivery. Emerging photocurable prepolymers such as PEG-based crosslinkers enable
the fabrication of biocompatible microgel particles by photolithography technique [85–87].
The advantage of photolithography particle fabrication is excellent shape fidelity down to
the submicrometer level, and the process can be high-throughput. Nearly all studies to date
involve robust crosslinked PEG microgels that exhibit negligible cytotoxicity and no
degradation. The introduction of labile linkages onto the prepolymer as addressed in
microfluidic method could become a strategy for the synthesis of biodegradable lithography
particles.
3.3. Particle Replication in Non-wetting Templates (PRINT®) and other micromolding
methods
The method involving soft-lithography-based micromolding with lift-off strategy pioneered
by Whitesides et al., has also been developed to fabricate engineered particles with control
over size and shape [88]. This method takes advantage of a template master generated by
photolithography for desired feature size and shape. An elastomeric mold is replicated from
this rigid master, creating an array of cavitary structures. Micromolding was early
envisioned as a low-cost tool using a PDMS stamp for micro and nanoscale pattern
replication rather than the fabrication of distinct particles. This is due to the challenge of
removing the residual layer (flash layer) that connects the particles. A micromolding
technique called PRINT (Particle Replication in Non-wetting Templates) utilizing a
fluorinated elastomeric mold was developed by DeSimone and colleagues in 2005, as the
first micromolding example for the scalable fabrication of distinct particles without the
formation of a flash layer [89].
In PRINT process, the synthesis of a photocurable, perfluoropolyether (PFPE)-based
elastomer (Fluorocur™), enabled the molding of patterned surfaces with improved master-
to-template fidelity and reproducibility at smaller feature sizes compared to silicone-based
elastomers [90, 91]. As shown in Fig. 4, the durable perfluoropolyether (PFPE) molds with
size- and shape-specific cavities are replicated from a master template [92, 93]. To create the
PFPE molds, liquid PFPE resin is drop cast on a silicon master and further cured onto a
backing poly(ethylene terephthalate) (PET) film. The PFPE mold can be used in a roll-to-
roll system for large scale production of particles [94]. As PFPE molds exhibit non-wetting
behavior and excellent compatibility to most liquid materials, the cavities are easily filled by
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liquid particle matrices, including solutions of organic solvents, monomers, polymers,
aqueous protein solutions, and biologics. Once the liquid particle precursor fills the cavities
and are solidified, the array of particles can be removed from the mold and collected.
The PRINT process enables large scale fabrication of precisely defined nanoparticles with
control over particle size (20 nm to 100 micron) and shape based on the master template
[95]. The PRINT process enables the mapping of important variables in nanomedicine, such
as the interdependency of the physical parameters of the particles — size, shape, mechanical
property, chemical composition and surface chemistry — on biodistribution, bioavailability,
and therapeutic efficacy for medical applications [25, 28, 44]. Monodisperse PRINT
particles have been loaded with a variety of cargos, including therapeutics, oligonucleotides,
vaccines, proteins, siRNA, and imaging agents [96]. Triggered release of this cargo has been
an active area of research in our lab, as we have explored a variety of stimuli-responsive
biomaterials.
PLGA PRINT particles have been successfully fabricated in a wide variety of size and shape
[97]. In the typical PRINT process, filling PLGA polymers into the mold cavities requires a
phase transition step. A film of PLGA polymer is cast to a desired thickness and is briefly
heated upon contact with a mold, allowing the polymer to flow into the wells by capillary
force. As the polymer is cooled below its phase transition temperature, the particles solidify.
The particles can then be transferred from the mold to a sacrificial layer (polyvinyl alcohol)
by briefly reheating when in contact with a harvesting surface. The particles can then be
collected by separating particles from the sacrificial harvesting layer. Several shapes have
been fabricated, as shown in Fig.5.
The PRINT process has exhibited enhanced drug loading with higher encapsulation
efficiency when compared to traditional solvent emulsification methods. In 200×200 nm
cylindrical PLGA particles, the concentration of loaded docetaxel ranges from 0% to 40%
with an encapsulation efficiency over 90%. Differential scanning calorimetry study
demonstrated that the drug was not crosslinked to the polymer and had not undergone fusion
or crystallization. Blank PLGA particles without drug were nontoxic to SKOV3 (ovarian
carcinoma) cells. However, docetaxel-loaded PLGA 200x200nm particles exhibited dose-
dependent cytotoxicity and were toxic in sub-nanomolar docetaxel concentrations. These
results demonstrated that the PRINT process allows for high encapsulation of docetaxel but
also high cytotoxicity when delivering docetaxel.
PRINT particles containing disulfide cross-linker have been fabricated to release a
chemotherapy agent and degrade in a reducing environment. These stimuli-responsive
particles were generated from the co-polymerization of several liquid monomers in the mold
under UV irradiation [98]. A prepolymer solution consisting of a disulfide cross-linker (Fig
6), an inert cross-linker, aminoethylmethacrylate, photoinitiator, and cargo (Doxorubicin)
was filled in mold cavity and photopolymerized. The particles containing 30 wt% disulfide
crosslinker were stable in phosphate buffered saline (PBS) solution, but the particles
released doxorubicin upon the addition of a reductive agent of 100 mM dithiothreitol (DTT).
The control particle without the disulfide crosslinker was stable in a 100 mM DTT PBS
solution. The control particles were extremely biocompatible, with cell viability at the
highest dosing of blank PRINT particles (0.64 mg/mL) showing no cytotoxicity. PRINT
particles dosing 2 wt. % Doxorubicin with 30 wt% disulfide cross-linker were efficient at
killing HeLa cells with more than 50% of the cells killed at a dosing of 160 µg/mL PRINT
particles, while PRINT particles dosing 2 wt. % Doxorubicin without the reductively labile
crosslinker showed no cellular toxicity.
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A group of novel pH-sensitive crosslinkers were fabricated for release of drugs in tumor
environment and an endosomal compartment. The pH-sensitive crosslinkers were
bifunctional silyl ether crosslinkers prepared with a variety of substituents on the silicon
atom; the collection included dimethylsilyl (DMS), diethylsilyl (DES), diisopropylsilyl
(DIS), and di-tert-butylsilyl (DTS) ether crosslinkers (Fig. 7A) [44]. The silyl ether-based
crosslinkers were photopolymerized with PEG diacrylate to create PRINT microparticles.
Two particle shapes were fabricated – 5 µm cube particles and 3 µm hexnut particles. The
release kinetics of a dye from the cubic particles were analyzed at two different pH values.
Rhodamine-B release as a function of time was evaluated for the particles fabricated with
the DMS crosslinker, which displayed an accelerated rate of degradation when dispersed in
a medium buffered at pH 5.0 and exhibited a degradation half-life of 0.091 days (2.19
hours). The same particles dispersed in a medium buffered at pH 6.0 had a half-life of 1.08
days, and particles dispersed in a medium buffered at pH 7.4 had a half-life of 2.94 days.
Intracellular degradation of the silyl ether PRINT particles was evaluated using TEM
(Figure 7B). Hexnut shaped particles were chosen for the studies because the unique shape
was easily distinguishable from other intracellular components. Two batches of particles
were evaluated, particles made with the rapidly degrading crosslinker (DMS) and particles
made with the non-degrading crosslinker (DTS). A positively charged component was added
to the particle matrix (N-(3-aminopropyl)methacrylamide hydrochloride) to ensure cellular
internalization by HeLa cells. As a function of the TEM bright-field mode, low-density
material appeared white and high-density material appeared dark. Figure 7B-a shows one
internalized DMS particle and three DMS particles outside of the cell. The internalized
particle (Figure 7B-b) appeared less dense than the particles outside of the cell (Figure 7B-
c). The DMS particles appeared to undergo a change in density by swelling (Figure 7B-d),
fragmenting (Figure 7B-e), and undergoing surface erosion (Figure 7B-f). DTS particles
were also internalized and exposed to the acidic environment of the endosome and
lysosome; however, there was no noticeable change in the size, shape, and density of the
DTS particles. The particles were not susceptible to degradation because of the stability of
the DTS crosslinkers.
Furthermore, protein particles were fabricated for the encapsulation and delivery of
macromolecular biological cargos. The degradation products of proteins or proteins
themselves are biocompatible and nontoxic. Insulin, albumin, and albumin mixtures with
siRNA or paclitaxel were molded into shape-specific particles on the basis of PRINT
technique. Molding these protein complex was performed by a lamination technique where
an aqueous protein solution (25 wt%) was placed between PFPE mold and another cover
film. An applied pressure can remove the excess protein solution, leaving a filled PFPE
mold without the formation of flash layer on top. Solid protein particles were lyophilized in
the mold and free particles were harvested from a sacrificial layer. Particles with control
over size and shape, 2 µm, 5 µm, 200 nm cubes and cylinders were successfully generated.
Overall, the PRINT technology offers a facile, rapid, and gentle fabrication process for
shape-specific, monodisperse protein particles using any protein [99]. There are ongoing
efforts to investigate numerous other proteins, including hormones, antibodies, and
enzymes. Recently, micromolding methods using other elastomeric molds (e.g. PDMS,
hydrogel) have also been emerged to create engineered particles with control over size and
shape, although a careful process is required for the removal of the flash layer on the
particles.
Rather than regular photolithography method, these additional micromolding methods are
also able to broadly mold biodegradable polymers, photocurable prepolymers, or gelators,
leading to the creation of biodegradable engineered particles. However, an examination of
solvent and particle precursor is necessary to demonstrate if the mold can be compatible
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with them. The particle fabrication process is similar to PRINT, beginning with mold filling
with a particle precursor followed by subsequent particle solidification, and finishing with
particle isolation. [100–102]. For example, thermoplastic PLGA particles with highly
uniform size and a plate-like morphology were produced by micromolding method using
PDMS mold [103, 104]. Specifically, the microwells on PDMS mold were filled by dipping
the mold in a PLGA acetone solution and followed by evaporation of the solvent. At 3 wt%,
a PLGA film covered the whole PDMS stamp. PLGA on the surface of protruding
microfeatures were transferred onto a substrate before the PLGA particles in the mold
cavities were isolated onto a poly(vinyl alcohol) layer. Free particles were eventually
separated from the poly(vinyl alcohol) by dissolution of the poly(vinyl alcohol). In addition,
a gelatin-based mold has also been used, which can resist particular organic solvents such as
methylene chloride that is a good solvent to PLGA but can extensively swell PDMS. The
gelatin-based mold was replicated by initially molding a gelatin solution onto a silicon
master with a subsequent sol-gel transition by temperature reduction. The patterned gel
played the same role as the regular PDMS mold in the micromolding process, capable of
creating one PLGA particle per well. A PLGA methylene chloride-drug solution was spread
onto the gelatin-based mold, allowing the pre-particle solution to fill each well before
solvent evaporation. Taking advantage of reversible sol-gel conversion, the drug-loaded
PLGA particles could be easily separated from the gel mold. Cargo release study indicated
that the PLGA particles were able to be biodegraded after the entire micromolding process.
An enzyme-triggered, cleavable peptide linkage was incorporated into particles fabricated
by micromolding from a quartz template [105]. A solution of diacrylated peptide with a
sequence of Gly-Phe-Leu-Gly-Lys (diacrylated GFLGK) was mixed with an inert
crosslinker (PEG diacrylate), cast onto a sacrificial layer (PVA), and molded by the quartz
template. The particles were solidified under exposure to UV irradiation. It is worth noting
that there was an excess layer connecting all of the particles. Oxygen plasma etching was
necessary to remove this residual layer, resulting in isolated particles. The uniform particle
size was 50 nm with well-controlled shape. The tetra-peptide sequence of GFLG in
diacrylated GFLGK was sensitive to lysosomal thiol proteases, particularly Cathepsin B (a
cysteine protease). Cathepsin B levels in tumor cells and tissues of patients with lung cancer
are significantly elevated and the GFLG-containing particle could conceivably be used as an
anticancer treatment. Consequently, the particles composed of equimolar diacrylated
GFLGK and PEG diacrylate began to degrade within 30 min and fully degraded between 24
h and 48 h, in the presence of 25 U/mL Cathepsin B in pH 5 PBS (Fig. 8). Bioactive
antibodies and nucleic acids were encapsulated within the particles, and the cargo was
released by this enzymatic trigger.
4. Conclusion and Future Prospects
An increasing number of stimuli-responsive materials are expected to be used in top-down
particle engineering methods. The combination of stimuli-responsive materials and top-
down fabrication methods allow for active tailoring of drug delivery to specific sites of
interest. Research regarding stimuli-responsive materials and top-down particle fabrication
methods is still in early developmental stages and much work will need to be conducted for
achieving clinical application. The major physiological stimuli that can trigger drug release
and particle degradation, including pH gradient, redox gradient, and enzymatic response, can
reduce side effects and enhance the effectiveness of certain medicines. Drug loading and
release profiles have been well characterized in certain stimuli-responsive microgel particles
and biodegradable polymeric particles, and thus, these systems will be considered as major
candidates for engineering of drug vehicles. All in all, stimuli-responsive engineering
nanomedicines can shift the paradigm in the delivery of medicine and diagnostics.
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(A) Microfluidic devices for the fabrication of monodisperse emulsion droplets (a) T-
junction type; (b) Flow focusing Device (FFD). Reproduced from Ref. 58 with permission
of Institute of Physics. (B) An experimental setup of Continuous Flow Lithography (CFL).
Polymerized particles are generated in the monomer stream flowing through the channel, by
a mask-defined UV light beam emanating from the objective. Reproduced from Ref. 63 with
permission of Nature Publishing Group.
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(A) Microparticles prepared via microfluidics with average size of: (a) 41 µm, (b) 11 µm.
(B) The comparison of drug-release profiles from monodisperse microparticles prepared
with microfluidic devices and polydisperse microparticles prepared using the conventional
single emulsion technique. Reproduced from Ref. 71 with permission of John Wiley &
Sons, Inc.
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Schematic illustration of the photolithography method to engineer shape and size specific
particles.
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General schematic representation of Particle Replication In Non-wetting Templates
(PRINT).
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PRINT PLGA nano- and microparticles. (A) 80 nm × 320 nm cylinders, (B) 200 nm × 200
nm cylinders, (C) 200 nm × 600 nm cylinders, (D) 1 µm sphere approximates, (E) 2 µm
cubes with ridges, and (F) 3 µm particles with center fenestrations. Scale bars: (A) 5 µm, (B)
4 µm, (C) 3 µm, (D) 10 µm, (E) 3 µm, and (F) 20 µm. Reproduced from Ref. 97 with
permission of American Chemical Society.
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Building blocks for the reductively labile PRINT particles.
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(A) Synthesis of photo-curable silyl ether cross-linkers. (B) TEM micrographs of PRINT
hexnut particles incubated in HeLa cells: (a–f) rapidly degrading hexnut particles fabricated
from the DMS cross-linker [scale bars: (a) 10 µm; (b–f) 0.5 µm; (g, h) nondegrading hexnut
particles fabricated from the DTS cross-linker (scale bars: 0.5 µm). Reproduced from Ref.
44 with permission of American Chemical Society.
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The enzymatically-triggered biodegradation of micromolding GFLGK particles.
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